Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
暂无分享,去创建一个
J. García-Saenz | M. Cebollero | I. Márquez-Rodas | S. López-Tarruella | Y. Jerez | E. Álvarez | D. Marrupe | M. del Monte-Millán | S. Enrech | T. Massarrah | I. Ocaña | M. Á. Lara Álvarez | D. Moreno Muñoz | Miguel Martín | A. Arias | C. Olier Garate | I. Echavarria Diaz-Guardamino | B. Herrero Lopez | S. Gamez Casado | Marta Roche-Molina | Fernando Moreno Antón | Coralia Bueno Muiño
[1] S. Jaffer,et al. Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer , 2022, Cancer.
[2] A. Prat,et al. A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes , 2022, NPJ breast cancer.
[3] P. Fasching,et al. Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] E. Rutgers,et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] M. Ellis,et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group , 2020, Journal of the National Cancer Institute.
[6] K. Czene,et al. Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer , 2020, JNCI cancer spectrum.
[7] M. Gnant,et al. Breast cancer , 2019, Nature Reviews Disease Primers.
[8] L. Saal,et al. Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer , 2019, Breast Cancer Research and Treatment.
[9] F. Cardoso,et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Mitch Dowsett,et al. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer , 2018, Nature Reviews Clinical Oncology.
[11] A. Arance,et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.
[12] E. Mardis,et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay , 2015, BMC Medical Genomics.
[13] A. Luini,et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.
[14] Kathleen A Cronin,et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.
[15] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] S. Rodenhuis,et al. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response , 2013, Breast Cancer Research and Treatment.
[17] P. Neven,et al. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[19] W. Sauerbrei,et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration , 2012, PLoS medicine.
[20] R. Gelber,et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[22] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[23] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.